183 related articles for article (PubMed ID: 25028367)
1. USP9X downregulation renders breast cancer cells resistant to tamoxifen.
Oosterkamp HM; Hijmans EM; Brummelkamp TR; Canisius S; Wessels LF; Zwart W; Bernards R
Cancer Res; 2014 Jul; 74(14):3810-20. PubMed ID: 25028367
[TBL] [Abstract][Full Text] [Related]
2. HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.
Jin K; Park S; Teo WW; Korangath P; Cho SS; Yoshida T; Győrffy B; Goswami CP; Nakshatri H; Cruz LA; Zhou W; Ji H; Su Y; Ekram M; Wu Z; Zhu T; Polyak K; Sukumar S
Cancer Discov; 2015 Sep; 5(9):944-59. PubMed ID: 26180042
[TBL] [Abstract][Full Text] [Related]
3. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
[TBL] [Abstract][Full Text] [Related]
4. Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells.
Kim SS; Lee MH; Lee MO
Breast Cancer Res Treat; 2020 Feb; 180(1):45-54. PubMed ID: 31897900
[TBL] [Abstract][Full Text] [Related]
5. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions.
Wen J; Li R; Lu Y; Shupnik MA
Oncogene; 2009 Jan; 28(4):575-86. PubMed ID: 18997820
[TBL] [Abstract][Full Text] [Related]
6. Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer.
Ghayad SE; Vendrell JA; Bieche I; Spyratos F; Dumontet C; Treilleux I; Lidereau R; Cohen PA
J Mol Endocrinol; 2009 Feb; 42(2):87-103. PubMed ID: 18984771
[TBL] [Abstract][Full Text] [Related]
7. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
8. VAV3 mediates resistance to breast cancer endocrine therapy.
Aguilar H; Urruticoechea A; Halonen P; Kiyotani K; Mushiroda T; Barril X; Serra-Musach J; Islam A; Caizzi L; Di Croce L; Nevedomskaya E; Zwart W; Bostner J; Karlsson E; Pérez Tenorio G; Fornander T; Sgroi DC; Garcia-Mata R; Jansen MP; García N; Bonifaci N; Climent F; Soler MT; Rodríguez-Vida A; Gil M; Brunet J; Martrat G; Gómez-Baldó L; Extremera AI; Figueras A; Balart J; Clarke R; Burnstein KL; Carlson KE; Katzenellenbogen JA; Vizoso M; Esteller M; Villanueva A; Rodríguez-Peña AB; Bustelo XR; Nakamura Y; Zembutsu H; Stål O; Beijersbergen RL; Pujana MA
Breast Cancer Res; 2014 May; 16(3):R53. PubMed ID: 24886537
[TBL] [Abstract][Full Text] [Related]
9. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.
Bièche I; Girault I; Urbain E; Tozlu S; Lidereau R
Breast Cancer Res; 2004; 6(3):R252-63. PubMed ID: 15084249
[TBL] [Abstract][Full Text] [Related]
10. Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells.
Gao P; Wang X; Jin Y; Hu W; Duan Y; Shi A; Du Y; Song D; Yang M; Li S; Han B; Zhao G; Zhang H; Fan Z; Miao QR
Breast Cancer Res; 2018 Sep; 20(1):112. PubMed ID: 30208932
[TBL] [Abstract][Full Text] [Related]
11. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
[TBL] [Abstract][Full Text] [Related]
12. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
[TBL] [Abstract][Full Text] [Related]
13. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.
Bergamaschi A; Christensen BL; Katzenellenbogen BS
Breast Cancer Res; 2011 Jun; 13(3):R70. PubMed ID: 21707964
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors.
Notas G; Pelekanou V; Kampa M; Alexakis K; Sfakianakis S; Laliotis A; Askoxilakis J; Tsentelierou E; Tzardi M; Tsapis A; Castanas E
Mol Oncol; 2015 Nov; 9(9):1744-59. PubMed ID: 26115764
[TBL] [Abstract][Full Text] [Related]
15. Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance.
Busch S; Sims AH; Stål O; Fernö M; Landberg G
Cancer Res; 2015 Apr; 75(7):1457-69. PubMed ID: 25833830
[TBL] [Abstract][Full Text] [Related]
16. UCH-L1-mediated Down-regulation of Estrogen Receptor α Contributes to Insensitivity to Endocrine Therapy for Breast Cancer.
Chen XS; Wang KS; Guo W; Li LY; Yu P; Sun XY; Wang HY; Guan YD; Tao YG; Ding BN; Yin MZ; Ren XC; Zhang Y; Chen CS; Ye YC; Yang JM; Cheng Y
Theranostics; 2020; 10(4):1833-1848. PubMed ID: 32042339
[No Abstract] [Full Text] [Related]
17. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
[TBL] [Abstract][Full Text] [Related]
18. Measuring IGF-1, ER-α and EGFR expression can predict tamoxifen-resistance in ER-positive breast cancer.
Chong K; Subramanian A; Sharma A; Mokbel K
Anticancer Res; 2011 Jan; 31(1):23-32. PubMed ID: 21273576
[TBL] [Abstract][Full Text] [Related]
19. Expression of the CD59 Glycoprotein Precursor is Upregulated in an Estrogen Receptor-alpha (ER-α)-Negative and a Tamoxifen-Resistant Breast Cancer Cell Line In Vitro.
Xiong H; Jin X; You C
Med Sci Monit; 2018 Nov; 24():7883-7890. PubMed ID: 30391994
[TBL] [Abstract][Full Text] [Related]
20. MLL3 is a de novo cause of endocrine therapy resistance.
Stauffer KM; Elion DL; Cook RS; Stricker T
Cancer Med; 2021 Nov; 10(21):7692-7711. PubMed ID: 34581028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
